EcoDrugPlus

Opioid Receptor Mu 1

Ensembl ID : ENSBTAG00000019719
Gene Symbol: OPRM1
9 Enzyme and pathways 5 Cross references
229 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSBTAG00000049473
Gene Symbol: OPRL1
7 Enzyme and pathways 5 Cross references
214 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSBTAG00000019772
Gene Symbol: OXTR
8 Enzyme and pathways 5 Cross references
277 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSBTAG00000013958
Gene Symbol: PAK4
12 Enzyme and pathways 4 Cross references
172 Possible Orthologues:

Pancreatic Lipase

Ensembl ID : ENSBTAG00000032237
Gene Symbol: PNLIP
9 Enzyme and pathways 5 Cross references
313 Possible Orthologues:

Pancreatic Polypeptide Receptor 1

Ensembl ID : ENSBTAG00000004760
Gene Symbol: PPYR1
7 Enzyme and pathways 4 Cross references
128 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSBTAG00000016948
Gene Symbol: PTH1R
6 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSBTAG00000008063
Gene Symbol: PPARA
16 Enzyme and pathways 5 Cross references
467 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSBTAG00000017542
Gene Symbol: PPARD
15 Enzyme and pathways 5 Cross references
432 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSBTAG00000001333
Gene Symbol: PPARG
6 Enzyme and pathways 5 Cross references
418 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSBTAG00000009232
Gene Symbol: PIK3CA
94 Enzyme and pathways 5 Cross references
146 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSBTAG00000006909
Gene Symbol: PIK3CB
57 Enzyme and pathways 5 Cross references
228 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).